0001628280-24-013295.txt : 20240327 0001628280-24-013295.hdr.sgml : 20240327 20240327160600 ACCESSION NUMBER: 0001628280-24-013295 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240327 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncology Institute, Inc. CENTRAL INDEX KEY: 0001799191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39248 FILM NUMBER: 24790605 BUSINESS ADDRESS: STREET 1: 18000 STUDEBAKER RD STREET 2: SUITE 800 CITY: CERRITOS STATE: CA ZIP: 90703 BUSINESS PHONE: 562-735-3226 MAIL ADDRESS: STREET 1: 18000 STUDEBAKER RD STREET 2: SUITE 800 CITY: CERRITOS STATE: CA ZIP: 90703 FORMER COMPANY: FORMER CONFORMED NAME: DFP HEALTHCARE ACQUISITIONS CORP. DATE OF NAME CHANGE: 20200108 8-K 1 toi-20240327.htm 8-K toi-20240327
0001799191false00017991912024-03-272024-03-270001799191us-gaap:CommonStockMember2024-03-272024-03-270001799191us-gaap:WarrantMember2024-03-272024-03-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

March 27, 2024
Date of Report (date of earliest event reported)
__________________________________________________________
The Oncology Institute, Inc.
(Exact name of registrant as specified in its charter)
__________________________________________________________
Delaware
(State or other jurisdiction of
incorporation or organization)
001-39248
(Commission File Number)
84-3562323
(I.R.S. Employer Identification Number)
18000 Studebaker Rd, Suite 800
Cerritos, California 90703
(Address of principal executive offices and zip code)
(562) 735-3226
(Registrant's telephone number, including area code)
__________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $0.0001TOIThe Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share
TOIIW
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company    ý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02. Results of Operations and Financial Condition

On March 27, 2024, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein.

The information contained in Items 2.02 of this Current Report and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section.
Item 9.01 - Financial Statements and Exhibits
(d) The following exhibits are being filed herewith:

Exhibit No.Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
        



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 27, 2024

The Oncology Institute, Inc.
By:
/s/ Mihir Shah
Name:
Mihir Shah
Title:
Chief Financial Officer

EX-99.1 2 item991-q42023earningsrele.htm EX-99.1 Document

image_0a.jpg

FOR IMMEDIATE RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024
CERRITOS, Calif., March 27, 2024 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2023.
Recent Operational Highlights
Remediated material weakness in Internal Controls over review of Complex Accounting Transactions.
Signed full-risk capitated contract in South Florida, effective January 1, 2024 and have now successfully onboarded the membership and the IPA providers.
Acquired and launched our California-based pharmacy in December and have already completed over 1,300 specialty medication fills.
Jeremy Castle enjoyed his first full quarter as our new Chief Operating Officer.
Hired 7 new providers in the quarter and ended the year with 69 clinics and 119 employed providers.
Fourth Quarter 2023 Financial Highlights
Consolidated revenue of $86 million, an increase of 20.1% compared to the prior year quarter
Gross profit of $14 million, a decrease of 8.0% compared to the prior year quarter
Net loss of $18.8 million compared to net loss of $11.0 million for the prior year quarter
Basic and diluted loss per share of $(0.21) and $(0.21), respectively, compared to $(0.12) and $(0.16) for the prior year quarter
Adjusted EBITDA of $(6.3) million compared to $(4.6) million for the prior year quarter
Cash, cash equivalents, and investments of $83 million as of December 31, 2023
Management Commentary
Daniel Virnich, CEO of TOI, commented, "I am very pleased with our performance in the fourth quarter of 2023, as we delivered strong growth, expanded our gross margin and reduced SG&A. Our full-risk capitated contract in South Florida is a significant milestone for TOI and we are excited to prove our model through this partnership. Our demonstrated ability to concurrently grow topline while improving margins lays the groundwork for continued success in 2024 and beyond."
Outlook for Fiscal Year 2024
TOI uses Adjusted EBITDA, a non-GAAP metric, as an additional tool to assess its operational performance. See "Financial Information: Non-GAAP Financial Measures" below. In reliance on the unreasonable efforts exception provided under Regulation S-K, TOI is not reasonably able to provide a quantitative reconciliation for forward-looking information of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure, without unreasonable efforts due to uncertainties regarding taxes, share-based compensation, goodwill impairment charges, change in fair value of liabilities, unrealized (gains) losses on investments, practice acquisition-related costs, consulting and legal fees, transaction costs and other non-cash items. The variability of these items could have an unpredictable, and potentially significant, impact on TOI’s future GAAP financial results. TOI expects interest expense in the range of $4 million to $5



million, other adjustment add backs in the range of $2 million to $4 million, and depreciation and amortization in the range of $4 million to $6 million.
2024 Guidance
Revenue$400 to $415 million
Gross Profit$68 to $79 million
Adjusted EBITDA$(8) to $(18) million
TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings. TOI's outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.
Fourth Quarter 2023 Results
Consolidated revenue for Q4 2023 was $86 million, an increase of 20.1% compared to Q4 2022, and a 4.6% increase compared to Q3 2023.
Revenue for patient services was $56 million, up 17.0% compared to Q4 2022. Growth in patient services revenue was driven by an increase in capitated contracts entered into during 2023 and in the latter half of 2022 as well as growth in fee-for-service ("FFS") revenue due to practice acquisitions and an overall increase in clinic count. Dispensary revenue increased 27.8% compared to Q4 2022 due to an increase in the number of filled prescriptions and an increase in the average revenue per filled prescription. Clinical trials & other revenue increased by 10.1% compared to Q4 2022 primarily due to an increase in Proposition 56 revenue and TOI Clinical Research revenue.
Gross profit in Q4 2023 was $14 million, a decrease of 8.0% compared to Q4 2022. The decrease was primarily driven by ongoing cost management fluctuations of oral and IV drugs. Gross profit is calculated by subtracting direct costs of patient services, dispensary, and clinical trials and other from consolidated revenues.
Selling, general and administrative ("SG&A") expenses in Q4 2023 were $28 million or 32.7% of revenue, compared with $30 million, or 41.4% of revenue, in Q4 2022 During Q4 2023, share-based compensation expense was $4 million. The decrease in SG&A expenses was due to restructuring in early 2023 and reduced overhead during the year.
Net loss for Q4 2023 was $18.8 million, a decrease of $7.7 million compared to Q4 2022 primarily due to an increase in operating revenue and decrease in SG&A expenses, offset by a decreased change in fair value of derivative liabilities and the goodwill impairment charge.
Adjusted EBITDA was $(6.3) million, an increase of $1.6 million compared to Q4 2022, primarily as a result of a decrease in share-based compensation and change in fair value of liabilities, offset by the goodwill impairment charge in Q4 2022.
Results for the Year Ended December 31, 2023
Consolidated revenue for the year ended December 31, 2023 was $324 million, an increase of 28.4% compared to the prior year.
Revenue for patient services was $214 million, an increase of 28.0% year-over-year. Growth in patient services revenue was primarily driven by an increase in capitated contracts entered into during the year ended December 31, 2023 and in the latter half of 2022 as well as growth in revenue from fee-for-service contracts due to practice acquisitions and an overall increase in clinic count. Dispensary revenue growth lagged the growth in revenue from patient services largely due to the Medi-Cal Rx transition. Despite the Medi-Cal Rx transition, dispensary revenue increased 30.9% compared to the comparable prior year period due to an increase in the average revenue per filled prescription. Clinical trials & other revenue increased by 8.6% compared to the prior year period due to an increase in miscellaneous contract revenue.
Revenue per capitated member was $39.5 PMPY (per member per year) at December 31, 2023, an increase of 10.5% compared to the prior year.
Gross profit for the year ended December 31, 2023 was $60 million, an increase of 14.4% year-over-year. The increase was driven by improved cost management of our oral and IV drugs and enhanced rebate opportunities.



SG&A expenses, excluding depreciation and amortization, for year ended December 31, 2023 were $114 million or 35.1% of revenue, compared with $120 million, or 47.4% of revenue, in the prior year. During 2023, share-based compensation expense was $18 million and SG&A related to transaction costs was $141 thousand. SG&A decline was primarily due to our restructuring in early 2023 and re-alignment of our vendors.
Net loss for the year ended December 31, 2023 was $83.1 million, a decrease of $83.2 million compared to the prior year, primarily due to the increase in gross profit and the change in the fair value of the warrant, earnout and conversion option derivative liabilities, offset by the goodwill impairment charge and increased operating expenses.
Adjusted EBITDA was $(25.8) million, an increase of $2.3 million compared to the prior year, primarily as a result of the change in fair value of the warrant, earnout and conversion option derivative liabilities.
Webcast and Conference Call
TOI will host a conference call on Wednesday, March 27, 2024 at 5:00 p.m. (Eastern Time) to discuss fourth quarter and full year results and management’s outlook for future financial and operational performance.
The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13744947. The replay will be available until April 3, 2024.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of TOI's website at https://investors.theoncologyinstitute.com.
About The Oncology Institute, Inc.
Founded in 2007, TOI and its affiliates are advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With approximately 120+ employed clinicians and more than 700 teammates at approximately 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “preliminary,” “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “predict,” “potential,” “guidance,” “approximately,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, anticipated financial results, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of TOI and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by anyone as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of TOI. These forward-looking statements are subject to a number of risks and uncertainties, including the accuracy of the assumptions underlying the 2024 outlook discussed herein, the outcome of judicial and administrative proceedings to which TOI may become a party or investigations to which TOI may become or is subject that could interrupt or limit TOI’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in TOI’s patient or payors' preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on TOI’s business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC, including the Item 1A. "Risk Factors" section of TOI's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 16, 2023 and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that TOI currently is evaluating or does not presently know or that TOI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect



TOI’s plans or forecasts of future events and views as of the date of this press release. TOI anticipates that subsequent events and developments will cause TOI’s assessments to change. TOI does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing TOI’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Financial Information; Non-GAAP Financial Measures
Some of the financial information and data contained in this press release, such as Adjusted EBITDA and revenue per capitated member, have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). TOI’s non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this press release in conjunction with TOI’s financial statements and the related notes thereto.
TOI believes that the use of Adjusted EBITDA provides an additional tool to assess operational and results of our performance, to plan and forecast future periods, and factors and trends in, and in comparing our financial measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in TOI's financial statements.
TOI defines Adjusted EBITDA as net (loss) income plus depreciation, amortization, interest, taxes, non-cash items, share-based compensation, goodwill impairment charges, change in fair value of liabilities, unrealized gains or losses on investments and other adjustments to add-back the following: consulting and legal fees related to acquisitions, one-time consulting and legal fees related to certain advisory projects, software implementations and debt or equity financings, severance expense and temporary labor and recruiting charges to build out our corporate infrastructure. A reconciliation of Adjusted EBITDA to net loss, the most comparable GAAP metric, is set forth below.
Adjusted EBITDA Reconciliation
Three Months Ended December 31,Change
(dollars in thousands)20232022$%
Net loss$(18,754)$(11,007)$(7,747)70.4 %
Depreciation and amortization1,577 1,192 385 32.3 %
Interest expense, net1,941 2,450 (509)(20.8)%
Income tax expense (benefit)(86)(367)281 (76.6)%
Non-cash addbacks(1)
1,876 604 1,272 210.6 %
Share-based compensation3,817 6,070 (2,253)(37.1)%
Goodwill impairment charges— 9,944 (9,944)N/A
Change in fair value of liabilities1,488 (15,482)16,970 (109.6)%
Unrealized (gains) losses on investments(206)(673)467 N/A
Practice acquisition-related costs(2)
91 (90)(98.9)%
Post-combination compensation expense(3)
487 155 332 N/A
Consulting and legal fees(4)
55 1,115 (1,060)(95.1)%
Infrastructure and workforce costs(5)
1,551 1,204 347 28.8 %
Transaction costs(6)
64 (63)(98.4)%
Adjusted EBITDA$(6,252)$(4,640)$(1,612)34.7 %
(1)    During the three months ended December 31, 2023, non-cash addbacks were primarily comprised of non-cash rent of $(83) and net bad debt write-offs of $1,989. During the three months ended December 31, 2022, non-cash addbacks were primarily comprised of net bad debt write-offs of $74 and non-cash rent of $531.
(2)    Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.
(3)    Deferred consideration payments for practice acquisitions that are contingent upon the seller’s future employment at the Company.



(4)    Consulting and legal fees were comprised of a subset of the Company’s total consulting and legal fees during the three months ended December 31, 2023 and 2022, and related to certain advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.
(5)    Infrastructure and workforce costs were comprised primarily of temporary labor of $148 and $724, recruiting expenses to build out corporate infrastructure of $633 and $406, as well as severance expenses resulting from cost rationalization programs of $81 and $45, and lease terminations, settlements, and penalty addbacks of $672 and $0 during the three months ended December 31, 2023 and 2022, respectively.
(6)    Transaction costs were comprised of legal and escrow fees associated with one practice acquisition for the three months ended December 31, 2023, and transactions costs incurred related to the issuance of the Senior Secured Convertible Note such as legal, audit, administrative, and registration fees for the three months ended December 31, 2022.
Adjusted EBITDA Reconciliation
Year Ended December 31,Change
(dollars in thousands)20232022$%
Net income (loss)$(83,068)$152 $(83,220)(54,750.0)%
Depreciation and amortization5,873 4,411 1,462 33.1 %
Interest expense, net6,777 4,082 2,695 66.0 %
Income tax expense (benefit)(36)(243)207 (85.2)%
Non-cash addbacks(1)
2,029 1,208 821 68.0 %
Share-based compensation17,548 27,683 (10,135)(36.6)%
Goodwill impairment charges16,867 9,944 6,923 N/A
Change in fair value of liabilities(1,395)(85,258)83,863 (98.4)%
Unrealized (gains) losses on investments(237)(640)403 N/A
Practice acquisition-related costs(2)
113 790 (677)(85.7)%
Post-combination compensation expense(3)
2,048 2,243 (195)N/A
Consulting and legal fees(4)
1,570 3,797 (2,227)(58.7)%
Infrastructure and workforce costs(5)
5,965 5,029 936 18.6 %
Transaction costs(6)
141 3,259 (3,118)(95.7)%
Adjusted EBITDA$(25,805)$(23,543)$(2,262)9.6 %
(1)    During the year ended December 31, 2023, non-cash addbacks were primarily comprised of net bad debt write-offs of $2,020. During the year ended December 31, 2022, non-cash addbacks were primarily comprised of a $476 of net bad debt write-off, deferred rent of $711, and other miscellaneous charges of $22.
(2)    Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.
(3)    Deferred consideration payments for practice acquisitions that are contingent upon the seller’s future employment at the Company.
(4)    Consulting and legal fees were comprised of a subset of the Company’s total consulting and legal fees during the years ended December 31, 2023 and 2022, and related to certain advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.
(5)    Infrastructure and workforce costs were comprised of recruiting expenses to build out corporate infrastructure of $2,227 and $2,835, software implementation fees of $105 and $116, severance expenses resulting from cost rationalization programs of $979 and $248, temporary labor of $1,365 and $1,829, and lease terminations, settlements, and penalty addbacks of $1,289 and $0 during the years ended December 31, 2023 and 2022, respectively.
(6)    Transaction costs were comprised of consulting, legal, administrative and regulatory fees associated with share repurchases and practice acquisitions during the year ended December 31, 2023, and related to the Senior Secured Convertible Note during the year ended December 31, 2022.
TOI defines revenue per capitated member as capitated revenue divided by lives under value-based contracts. TOI believes that use of revenue per capitated member is an appropriate measure of individual value-based contract economics as our business takes on adjacent specialty risk and establishes more Medicare Advantage only contracts outside of California. This will provide a clearer picture of the impact of incremental contracts signed and growth across markets and to provide more clarity to analysts and shareholders. A reconciliation of revenue per capitated member (PMPY) to capitated revenue, the most comparable GAAP metrics, is set forth below:



Year Ended December 31,
20232022
Capitated revenue (dollars in thousands)$70,370 $61,341 
Lives under value-based contracts (millions)1.8 1.7 
Revenue per capitated member (PMPY)$39.5 $35.7 
TOI uses revenue per capitated member, a non-GAAP metric, as an additional tool to assess its value-based contract economics. See "Financial Information: Non-GAAP Financial Measures" above. In reliance on the unreasonable efforts exception provided under Regulation S-K, TOI is not reasonably able to provide a quantitative reconciliation for forward-looking information of revenue per capitated member to capitated revenue, the most directly comparable GAAP financial measure, without unreasonable efforts due to uncertainties regarding future capitated contracts, on-going contract negotiations, unpredictability for care of various patients, and fluctuations in lives under value-based contracts.
Key Business Metrics
Three Months Ended December 31,Year Ended December 31,
2023202220232022
Clinics (1)
83 76 83 76 
Markets15 15 15 15 
Lives under value-based contracts (millions)1.8 1.7 1.8 1.7 
Net income (loss)$(18,754)$(11,007)$(83,068)$152 
Adjusted EBITDA (in thousands)$(6,252)$(4,640)$(25,805)$(23,543)
(1)    Includes independent oncology practices to which we provide limited management services, but do not bear the operating costs.



Consolidated Balance Sheets (Unaudited)
(in thousands except share data)
December 31, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$33,488 $14,010 
Marketable securities49,367 59,796 
Accounts receivable, net42,360 39,816 
Other receivables551 617 
Inventories13,678 9,261 
Prepaid expenses and other current assets4,049 6,918 
Total current assets143,493 130,418 
Non-current investments— 58,354 
Property and equipment, net10,883 8,547 
Operating right of use assets29,169 24,494 
Intangible assets, net17,904 17,957 
Goodwill7,230 21,418 
Other assets561 477 
Total assets$209,240 $261,665 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$14,429 $9,372 
Current portion of operating lease liabilities6,363 5,498 
Income taxes payable— 255 
Accrued expenses and other current liabilities13,996 14,595 
Total current liabilities34,788 29,720 
Operating lease liabilities26,486 22,060 
Derivative warrant liabilities636 350 
Derivative earnout liabilities— 803 
Conversion option derivative liabilities3,082 3,960 
Long-term debt, net of unamortized debt issuance costs86,826 80,621 
Other non-current liabilities365 868 
Deferred income taxes liability32 108 
Total liabilities152,215 138,490 
Stockholders’ equity:
Common Stock, 0.0001 par value, authorized 500,000,000 shares; 75,879,025 shares issued and 74,145,251 shares outstanding at December 31, 2023 and 73,265,621 shares issued and outstanding at December 31, 2022
Series A Convertible Preferred Stock, 0.0001 par value, authorized 10,000,000 shares; 165,045 shares issued and outstanding at December 31, 2023 and December 31, 2022
— — 
Treasury Stock at cost, 1,733,774 and 0 shares at December 31, 2023 and December 31, 2022
(1,019)— 
Additional paid-in capital204,186 186,250 
Accumulated deficit(146,150)(63,082)
Total stockholders’ equity57,025 123,175 
Total liabilities and stockholders’ equity$209,240 $261,665 




Consolidated Statements of Operations (Unaudited)
(in thousands except share data)
Three Months Ended December 31,Year Ended December 31,
2023202220232022
Revenue
Patient services$56,171 $47,992 $213,504 $166,785 
Dispensary27,607 21,607 103,835 79,343 
Clinical trials & other2,010 1,825 6,900 6,355 
Total operating revenue85,788 71,424 324,239 252,483 
Operating expenses
Direct costs – patient services48,364 38,382 181,017 134,761 
Direct costs – dispensary22,743 17,295 83,071 65,111 
Direct costs – clinical trials & other302 118 578 518 
Goodwill impairment charges— 9,944 16,867 9,944 
Selling, general and administrative expense28,090 29,572 113,851 119,689 
Depreciation and amortization1,577 1,192 5,873 4,411 
Total operating expenses101,076 96,503 401,257 334,434 
Loss from operations(15,288)(25,079)(77,018)(81,951)
Other non-operating expense (income)
Interest expense, net1,941 2,450 6,777 4,082 
Change in fair value of derivative warrant liabilities344 (1,398)286 (1,843)
Change in fair value of earnout liabilities(11)(5,394)(803)(59,215)
Change in fair value of conversion option derivative liabilities1,156 (8,690)(878)(24,200)
Gain on loan forgiveness— — — (183)
Other, net123 (673)704 (501)
Total other non-operating loss expense (income)3,553 (13,705)6,086 (81,860)
Loss before provision for income taxes(18,841)(11,374)(83,104)(91)
Income tax benefit (expense)87 367 36 243 
Net income (loss)$(18,754)$(11,007)$(83,068)$152 
Net income (loss) per share attributable to common stockholders:
Net income (loss) attributable to common stockholders, basic(15,314)(8,972)(67,877)68 
Weighted-average number of shares outstanding, basic73,469,10172,751,84773,748,66072,793,497
Net income (loss) per share attributable to common stockholders, basic$(0.21)$(0.12)$(0.92)$— 
Net loss attributable to common stockholders, diluted(15,314)(13,893)(67,877)(16,980)
Weighted-average number of shares outstanding, diluted73,469,10185,591,81473,748,66080,605,600
Net loss per share attributable to common stockholders, diluted$(0.21)$(0.16)$(0.92)$(0.21)



Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Three Months Ended December 31,Year Ended December 31,
2023202220232022
Cash flows from operating activities:
Net income (loss)$(18,754)$(11,007)$(83,068)$152 
Adjustments to reconcile net income (loss) to cash and cash equivalents used in operating activities:
Depreciation and amortization1,577 1,192 5,873 4,411 
Amortization of debt issuance costs and debt discount1,572 1,552 6,205 2,444 
Goodwill impairment charges— 9,944 16,867 9,944 
Share-based compensation4,079 6,070 17,810 27,683 
Change in fair value of liability classified warrants344 (1,398)286 (1,843)
Change in fair value of liability classified earnouts(11)(5,394)(803)(59,215)
Change in fair value of liability classified conversion option derivatives1,156 (8,690)(878)(24,200)
Unrealized (gain) loss on investments(194)316 (249)378 
Accretion of discount on investment securities(1,919)(991)(2,631)(1,020)
Deferred taxes(137)(446)(76)(263)
Gain on loan forgiveness— — — (183)
Bad debt expense 1,989 74 2,020 476 
(Gain) loss on disposal of property and equipment(30)(1)(30)21 
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable4,093 (5,070)(4,564)(20,285)
Inventories(1,472)852 (4,385)(1,732)
Other receivables(87)(58)66 620 
Prepaid expenses400 737 3,128 4,282 
Operating lease right-of-use assets1,358 1,684 5,806 5,404 
Other assets(1)(16)(84)(157)
Accrued expenses and other current liabilities2,778 (545)3,357 2,349 
Income taxes payable(255)(132)(255)123 
Accounts payable1,096 (1,783)5,057 (6,187)
Current and long-term operating lease liabilities(1,415)(803)(5,324)(3,801)
Other non-current liabilities(49)(84)(443)(1,157)
Net cash and cash equivalents used in operating activities(3,882)(13,997)(36,315)(61,756)
Cash flows from investing activities:
Purchases of property and equipment(861)(1,995)(4,567)(5,529)
Cash paid for practice acquisitions, net(156)(470)(4,456)(8,577)
Purchases of marketable securities/investments88 (30,106)(9,595)(117,508)
Sales of marketable securities/Investments12,556 — 81,258 — 
Net cash and cash equivalents provided by (used in) investing activities11,627 (32,571)62,640 (131,614)
Cash flows from financing activities:
Proceeds from issuance of long-term debt— — — 110,000 
Transactions costs related to issuance of long-term debt— — — (3,663)
Payments made for financing of insurance payments(259)(1,270)(3,269)(5,009)
Payment of deferred consideration liability for acquisition(1,625)— (2,584)(509)
Principal payments on financing leases(10)(19)(101)(58)
Common stock repurchase from related party— — (1,019)(9,000)
Common stock issued for options exercised113 442 126 858 
Taxes for common stock net settled— — — (413)
Net cash and cash equivalents (used in) provided by financing activities(1,781)(847)(6,847)92,206 
Net (decrease) increase in cash and cash equivalents5,964 (47,415)19,478 (101,164)
Cash and cash equivalents at beginning of period27,524 61,425 14,010 115,174 
Cash and cash equivalents at end of period$33,488 $14,010 $33,488 $14,010 



Contacts
Media
The Oncology Institute, Inc.
Daniel Virnich, MD
danielvirnich@theoncologyinstitute.com
(562) 735-3226 x 81125

Revive
Michael Petrone
mpetrone@reviveagency.com
(615) 760-4542
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com

EX-101.SCH 3 toi-20240327.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 toi-20240327_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 toi-20240327_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Redeemable Warrants Warrant [Member] Class of Stock [Domain] Class of Stock [Domain] City Area Code City Area Code Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Common Stock Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 toi-20240327_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0a.jpg LOGO begin 644 image_0a.jpg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htm IDEA: XBRL DOCUMENT v3.24.1
Cover Page
Mar. 27, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Mar. 27, 2024
Entity Registrant Name The Oncology Institute, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39248
Entity Tax Identification Number 84-3562323
Entity Address, Address Line One 18000 Studebaker Rd, Suite 800
Entity Address, City or Town Cerritos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90703
City Area Code 562
Local Phone Number 735-3226
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001799191
Amendment Flag false
Common Stock  
Document Information [Line Items]  
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol TOI
Security Exchange Name NASDAQ
Redeemable Warrants  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share
Trading Symbol TOIIW
Security Exchange Name NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +R >U@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "\@'M8D6!A"^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O31U"J'KBV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"-#E+W$9]C'S"2Q70SNLXGJ<.:'8F"!$CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1 $YW?@D)11I& "%F$ALK8Q6NJ(BOIXQAN]X,-G[&:8T8 =.O24H"HK8.TT M,9S&KH$K8((11I>^"V@6XES]$SMW@)V38[)+:AB&GQY=YW<+Z M1,IKS+^2E70*N&:7R:_UPV:W9:W@XK;@=2'N=X)+OI*K^GUR_>%W%7:]L7O[ MCXTO@FT#O^ZB_0)02P,$% @ O(![6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "\@'M8D[X%T1D% -%@ & 'AL+W=OT=+:(2*)*4G'\ M[7>4'^BFPJ9=4:7Y;69'EVJPB8R@YEFIDA3 MH3?O(%'KJX[?>;EP)U>Q=1>ZH\MOMLK]=A86&L2G?!2)#*;/LKGG<#L1R[;2P_$/M) MZ#/&^R>,>[SW=7@7,2H67K'P4B\XH'>MP@(3;MDTVY:;2]N_'_$I-K60FO^: M$+>2O69)5]-O32Y"N.I@T1K03] 9_?R3?^']1@ '%7! J=? ]YN\PDL9J@8R? M1=H(1NO5)@7QV"BFM*YTF7=G;"YQ4%D M2K.)*C*K-_@;-;+3XM)L ^%^D"=!,(K>%Y_FDPY+T!P3.H M> ;'\-R+9S:-L/;D4H;;Z7J8CE8<]$Z#\PL>\(# &U9XPV/PQE&$<]Z\B[!""HD5@G<(9-^KC=C[+NB).\/RNU?K MK-&;:;D):"VM,A3;7I/POXNMFALSK9YD%C8W#UIS,J;0ZI[ADP[_#=I,&2L2 M]H_,#T[8%L6AU_>H*O3K]N#3!E^F<(R+I<,HM #." JD;A$^[>P?58AC,HM5 M1OE'BT@_.#\-.+^@B.K.X-.6_H#%:2'#@4G3(MNYAVFDHH66(C% (=5=P*>= M>JX2&4HKLQ7[A.6MI4@:>6B55I[:\WW:L&<:3D,<'L#YM5UE0!:A]=PNEP?R M1^NUDM7N[]-F_0W9U)@"R5H!:=E6P-K__:,:P$T*>N7R^3LJV-@56RZR32,: M+6AU09'QVN7Y42Y_\\SN<4%D9-DTMRNWQM4MK=8V8KQV>'Z4PT\PFQJM8HJ) M?&8?H'&L6J2P4_K]X= ?^A39WD4S7W*KPL1&$#'_EQPBO79[W?L#W$VGZKV6N^P!O6=I+BVM:M60^_V7Q*YM# M6&!G:"X[6FF7'..2<\)RH=F32 I@;[PS5Y$4;=TB.&WN.&!V2H'4O8'37OXR3F@D82RR%1S\LFH1^CR>7X__I)CJKL!I^[Z#"" 5"\SG M@]#N.TN0]TT MKFOV.2M"CMY6B]R]$) Q'& M;!VK^B*#9]"A-.6#.$S,+1Q-+'1)\?5,*Z.%92)[B0*6:QF6C[[Q_;-SC^6X M*BC#J>&H>U5 -YCV6=@F<#N=/E H=7,*Z-YR_#QL$3H\#[M[FWMNH_23<&L: MPQ)8HI)WUD=;U-N]Q^V)57FYW[=0UJJT/(Q!X,+,/8#WETK9EQ.WA5CM (_^ M!U!+ P04 " "\@'M8GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67= MA['-HN6/O.-%Q[I#)6 M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-? MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@# ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\ M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/! MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V, MD_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]? M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD M\%G'!QR>(W?#$T%^@2O M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@/ M/GL?)=-[*CG_5U/\!%!+ P04 " "\@'M8EXJ[', 3 @ "P %]R M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_: MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$ MVV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( +R >U@9117U-P$ "<" M / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V- MB??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C! MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$ M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= 9. MMO8(72A]95,. 46=W=3%<]0!;\K!XVBLA H#E&^J%977DHHM)]W1ZTSO'R:/ M6D;KW$JY]_!*MAQSCG^T_ %02P,$% @ O(![6"0>FZ*M ^ $ !H M !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL M[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C] MLCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP M3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( +R >UAED'F2&0$ ,\# M 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@ M"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0" M50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M- M\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[ M0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TF MGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( +R >UB3O@71&04 T6 8 " @0X( M !X;"]W;W)K&POUB7BKL

U@9117U-P$ "<" / M " 2(1 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "\@'M8)!Z;HJT M #X 0 &@ @ &&$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " "\@'M899!YDAD! #/ P $P M@ %K$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "U% " ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 23 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.deitaxonomy.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports toi-20240327.htm toi-20240327.xsd toi-20240327_def.xml toi-20240327_lab.xml toi-20240327_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "toi-20240327.htm": { "nsprefix": "toi", "nsuri": "http://www.deitaxonomy.com/20240327", "dts": { "inline": { "local": [ "toi-20240327.htm" ] }, "schema": { "local": [ "toi-20240327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "definitionLink": { "local": [ "toi-20240327_def.xml" ] }, "labelLink": { "local": [ "toi-20240327_lab.xml" ] }, "presentationLink": { "local": [ "toi-20240327_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 26 }, "report": { "R1": { "role": "http://www.deitaxonomy.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "toi-20240327.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "toi-20240327.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfStockDomain", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockMember", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentInformationTable", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WarrantMember", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Warrants", "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.deitaxonomy.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001628280-24-013295-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-013295-xbrl.zip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toi-20240327_htm.xml IDEA: XBRL DOCUMENT 0001799191 2024-03-27 2024-03-27 0001799191 us-gaap:CommonStockMember 2024-03-27 2024-03-27 0001799191 us-gaap:WarrantMember 2024-03-27 2024-03-27 0001799191 false 8-K 2024-03-27 The Oncology Institute, Inc. DE 001-39248 84-3562323 18000 Studebaker Rd, Suite 800 Cerritos CA 90703 562 735-3226 false false false false Common stock, par value $0.0001 TOI NASDAQ Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share TOIIW NASDAQ true false